Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion Stereoselective Disposition and CYP2D6 Interactions
NCT03420469Phase 1Completed
- Sponsor
- Indiana University
- Start
- Jun 2018
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bupropion in major depressive disorder (MDD) and smoking cessation, sponsored by Indiana University. Primary endpoints: Exposure (Pharmacokinetics of Bupropion and Metabolites) and CYP2D6 Activity Inhibition. Started Jun 2018; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)smoking cessation
Beyond the preview
Go deeper on NCT03420469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03420469.